• By ICR Secretariat
  • Posted Monday, November 21, 2022

Under FDA pressure, GSK limits use of ovarian cancer drug


GSK will stop selling the drug Zejula for some ovarian cancer patients whose disease is stable after a second line of chemotherapy, the company said Friday, following pressure from the Food and Drug Administration to pull the medicine from the market in that setting.